查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1521976

全球精神分裂症药物市场：按分销管道、治疗类别、国家和公司分析（2024-2032）

Global Schizophrenia Drugs Market Report by Distribution Channel Treatment Therapeutic Class Countries and Company Analysis, 2024-2032
出版日期: | 出版商: Renub Research | 英文 165 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

精神分裂症药物市场分析

全球精神分裂症药物市场规模预计将从 2030 年的 74.331 亿美元增至 2032 年的 101.324 亿美元以上，2024 年至 2032 年复合年增长率为 3.50%。这种增长是由于精神分裂症盛行率的增加、药物处方的创新以及公众对精神疾病的瞭解的提高。

精神分裂症治疗药物市场前景

精神分裂症是一种急性和慢性精神疾病，会改变患者的行为。症状包括看到或听到不真实的事物、有奇怪的信念、难以做出决定或表达情绪。然而，研究表明，遗传、胎儿发育期间发生的事件（例如接触病毒、营养不良、压力情况等）以及大脑的内容和线路等因素的结合也可能是性别的原因。

精神分裂症主要采用抗精神病药物治疗，大致分为两类：第一代（典型）和第二代（非典型）。这两类药物作用于大脑中的神经传导物质以减轻症状。精神分裂症患者需要与他们的医疗保健提供者互动，以找出副作用最小的最佳药物。因此，精神分裂症的有效治疗和患者生活品质的改善取决于治疗和社会支持。

精神分裂症治疗药物市场的驱动因素

公营和私营部门的举措

与精神健康相关的政府政策和精神分裂症药物的补贴投资产生了巨大的影响。市场驱动因素包括政府对精神健康服务、基础设施发展、医疗改革和精神疾病人格解体的政策。额外的资金是推动药物开发创新和改善患者治疗效果的关键。以健康为中心的广告、学校和其他机构的特殊计画所创造的意识确保人们为自己寻求治疗和抗精神病药物。这些政府措施有助于使精神分裂症更容易控制，加强治疗方法和精神分裂症药物市场。

改善诊断和治疗设施

更好的诊断工具和治疗中心的可用性也有助于精神分裂症的早期诊断，以便及时采取适当的干预措施。CT 扫瞄、MRI、实验室检查（包括基因鑑定）和增强筛检技术等现代诊断方法可确保早期发现疾病，以便及早治疗。综合护理设施提供各种服务，包括药物治疗、心理治疗和服务支持，并被发现可以带来卓越的患者体验。这是因为透过早期诊断和早期干预，可以更好地控制疾病症状，从而改善大多数患者的生活方式并遵守医生的建议。被诊断出患有精神分裂症的患者越来越多地透过使用抗精神病药物进行治疗，从而推动了精神分裂症治疗药物的市场。

精神分裂症盛行率上升

世界各地的人们罹患精神分裂症的比率比以往任何时候都高。因此，需要更有效的药物治疗。随着被诊断出患有这种慢性精神疾病的患者数量增加，对新型有效抗精神病药物的需求也在增加。增加人们获取有关精神分裂症及其症状的资讯将改善就医行为。提高心理健康意识和更好地获得医疗服务也促成了这种情况。随着对精神分裂症患者评估的增加，对改善患者生活品质的新药和控制症状的优质治疗的需求不断增加。

亚太地区精神分裂症药物市场

目前，由于心理健康意识的提高和精神分裂症的高盛行率，亚太地区的精神分裂症治疗市场正在蓬勃发展。中国、印度、日本等国人口众多、医疗设施发达，并做出了重要贡献。透过政府措施和增加对医疗保健行业的投资来改善心理健康服务，这对市场成长产生了积极影响。然而，远离城市地区的耻辱和缺乏足够的精神卫生设施等问题仍然存在。不过，一些分析师认为，新药开发领域的持续研究和对心理健康服务的关注可能会促使市场稳定成长。

该报告审视了全球精神分裂症治疗药物市场，并提供市场成长驱动因素和课题、市场占有率分析、公司分析等。

目录

第1章 简介

第2章 研究方法

第3章 执行摘要

第4章 市场动态

  • 增长动力
  • 任务

第5章 全球精神分裂症治疗药物市场

第6章 市占率分析

  • 透过治疗
  • 按治疗类别
  • 按分销渠道
  • 按国家

第7章 治疗

  • 口服
  • 注射

第8章 治疗阶级

  • 第二代
  • 第三代
  • 其他

第9章 通路

  • 医院药房
  • 零售药店
  • 网上药店

第10章 国家

  • 美洲
    • 美国
    • 加拿大
    • 墨西哥
    • 巴西
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳大利亚
  • 中东/非洲
    • 南非
    • 阿拉伯联合酋长国
  • 其他地区

第11章 公司分析

  • H. Lundbeck A/S
  • Pfizer Inc.
  • AbbVie
  • AstraZeneca
  • Bristol Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis AG
  • Takeda Pharmaceuticals
简介目录

Schizophrenia Drugs Market Analysis

Global schizophrenia drugs market will increase from US$ 7,433.1 million in 2030 to over US$ 10,132.4 million by 2032 with a CAGR of 3.50% from 2024 to 2032. This growth is as a result of the growing incidences of schizophrenia, innovations in drug formulation, and enhancement of people's knowledge on mental illnesses.

Schizophrenia Drugs Market Outlook

Schizophrenia is an acute and chronic mental disorder that patient behavior. It results in different manifestations which include sees or hears things that are not real, has strange beliefs and has issues with decision making and demonstrating feelings. Nonetheless, studies show that it may be a combination of heredity, events that occur while the fetus is still developing (such as, being exposed to viruses, malnutrition or stressful situations), and the brain's contents and wiring that may also be attributed to it.

Schizophrenia is primarily treated with antipsychotic medications, which come in two main types: first generation (typical) and second generation (atypical). These two types of drugs function in that they tend to affect neurotransmitters within the brain in order to help to reduce the symptoms. Schizophrenia patients should have a mutual relationship with their health care givers with an aim of identifying the best drug that could be administered with minimal side effects. Thus, the effective treatment of schizophrenia and the upshot of the patients' quality of life depend on therapy and social support.

Driving Factors in the Schizophrenia Drugs Market

Government and Private Sector Initiatives:

Mental health related government policies and grant investment on schizophrenia drug have a very prominent influence. The factors driving the market include the government policies towards mental health services, development of infrastructure, healthcare reforms, and destigmatization of mental illness. Additional funding is the key to spurring innovation in the development of new medications and improving outcomes for patients. Awareness created by health-focused commercials, special programs in schools, and other institutions ensure that individuals seek treatment and seek antipsychotic drugs for themselves. Such governmental initiatives do make the environment more conducive toward managing schizophrenia and contribute to enhancing the treatment approaches and the market for the schizophrenia medications.

Improved Diagnostic and Treatment Facilities:

Availability of better diagnostic tools and treatment centers also helps in early diagnosis of schizophrenia and a proper intervention is taken on time. Modern diagnostic methods such as CT scans, MRIs, laboratory tests including gene identification and enhanced techniques of screening, make sure that the disorder is detected at a primary stage so as to be accorded an early treatment. It is observed that comprehensive care facility output a range of services that include medication, psychotherapy and service support leading to the improved patient's experiences. This is because symptoms of the disease are managed well through early diagnosis and intervention, hence lifestyles of most patients are enhanced, and they also comply with recommendations from practitioners. The patients diagnosed with schizophrenic disorders are encouraged to continue with the treatment through use of antipsychotic drugs thus promoting the market of schizophrenia drugs.

Rising Prevalence of Schizophrenia:

People around the world are developing schizophrenia at a higher rate than in the past; thus, there is needed a more effective medication solution for the disease. With patients diagnosed with this chronic mental disorder increasing in number, the requirement for new and effective antipsychotic drugs is also increasing. Higher incidence of public access to information on schizophrenia and its manifestation in people's lives improves healthcare seeking behavior. Raising awareness of mental health, and having access to better healthcare services also contributes to this scenario. Thus, an increase in the appreciation of schizophrenic patients results in the growth of demand for new drugs and improved treatments for controlling symptoms so as to enhance the client's quality of life.

Asia Pacific Schizophrenia Drugs Market

Currently, the Asia Pacific market for schizophrenia drug is trending due to the awareness of mental health and high prevalence of schizophrenia in the markets. Countries such as china India and Japan are indispensable contributors owning to their huge populace and enhancing health facility amenities. There is an emphasis on the improvement of mental health services through governmental actions and raising investments into the healthcare segment, which positively influence market growth. There are new and advanced antipsychotic drugs to help with the unmet medical requirements; however, there are continued problems like prejudice and lack of appropriate mental health facilities far from urban regions. However, some analysts agree that the market is likely to expand steadily due to continued research in the field of development of new medicines and the focus on mental health services.

Global Schizophrenia Drugs Company Analysis:

Schizophrenia Drugs market is stable and growing, leading companies like H Lundbeck, Pfizer Inc, AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Takeda Pharmaceuticals were actively participating in the market and continuously contributing in the development of the market.

Global Schizophrenia Drugs Company News:

March 2022: AbbVie and Gedeon Richter entered a partnership to develop and market dopamine receptor modulators for the potential treatment of neuropsychiatric disorders.

February 2022: Vanderbilt University partnered with Neumora Therapeutics to develop precision treatments for brain illnesses by combining data science and neuroscience, focusing on neuropsychiatric diseases like schizophrenia.

Treatment -Market Breakup in 2 Viewpoints -

1. Oral

2. Injectable

Therapeutic Class - Market Breakup in 3 Viewpoints -

1. Second Generation

2. Third Generation

3. Others

Distribution Channel - Market Breakup in 4 Viewpoints -

1. Hospital Pharmacies

2. Retail Pharmacies

3. Online Pharmacies

Geography - Market Breakup of 18 countries -

  • North America

United States

Canada

Mexico

Brazil

  • Europe

United Kingdom

Germany

France

Italy

Spain

Netherlands

  • Asia Pacific

China

Japan

India

South Korea

Australia

  • Middle East & Africa

South Africa

United Arab Emirates

  • Rest of the World

Company Insights:

  • Overview
  • Business Strategy
  • Product Portfolio
  • Financial Insight

Key Players Analysis:

1. H Lundbeck

2. Pfizer Inc.

3. AbbVie

4. AstraZeneca

5. Bristol Myers Squibb

6. Eli Lilly

7. GlaxoSmithKline

8. Johnson & Johnson

9. Novartis AG

10. Takeda Pharmaceuticals

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Global Schizophrenia Drugs Market

6. Market Share Analysis

  • 6.1 By Treatment
  • 6.2 By Therapeutic Class
  • 6.3 By Distribution Channel
  • 6.4 By Country

7. Treatment

  • 7.1 Oral
  • 7.2 Injectable

8. Therapeutic Class

  • 8.1 Second Generation
  • 8.2 Third Generation
  • 8.3 Others

9. Distribution Channel

  • 9.1 Hospital Pharmacies
  • 9.2 Retail Pharmacies
  • 9.3 Online Pharmacies

10. Country

  • 10.1 Americas
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
    • 10.1.4 Brazil
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
  • 10.4 Middle East & Africa
    • 10.4.1 South Africa
    • 10.4.2 United Arab Emirates
  • 10.5 Rest of the World

11. Company Analysis

  • 11.1 H. Lundbeck A/S
    • 11.1.1 Overview
    • 11.1.2 Business Strategy
    • 11.1.3 Product Portfolio
    • 11.1.4 Financial Insight
  • 11.2 Pfizer Inc.
    • 11.2.1 Overview
    • 11.2.2 Business Strategy
    • 11.2.3 Product Portfolio
    • 11.2.4 Financial Insight
  • 11.3 AbbVie
    • 11.3.1 Overview
    • 11.3.2 Business Strategy
    • 11.3.3 Product Portfolio
    • 11.3.4 Financial Insight
  • 11.4 AstraZeneca
    • 11.4.1 Overview
    • 11.4.2 Business Strategy
    • 11.4.3 Product Portfolio
    • 11.4.4 Financial Insight
  • 11.5 Bristol Myers Squibb
    • 11.5.1 Overview
    • 11.5.2 Business Strategy
    • 11.5.3 Product Portfolio
    • 11.5.4 Financial Insight
  • 11.6 Eli Lilly
    • 11.6.1 Overview
    • 11.6.2 Business Strategy
    • 11.6.3 Product Portfolio
    • 11.6.4 Financial Insight
  • 11.7 GlaxoSmithKline
    • 11.7.1 Overview
    • 11.7.2 Business Strategy
    • 11.7.3 Product Portfolio
    • 11.7.4 Financial Insight
  • 11.8 Johnson & Johnson
    • 11.8.1 Overview
    • 11.8.2 Business Strategy
    • 11.8.3 Product Portfolio
    • 11.8.4 Financial Insight
  • 11.9 Novartis AG
    • 11.9.1 Overview
    • 11.9.2 Business Strategy
    • 11.9.3 Product Portfolio
    • 11.9.4 Financial Insight
  • 11.10 Takeda Pharmaceuticals
    • 11.10.1 Overview
    • 11.10.2 Business Strategy
    • 11.10.3 Product Portfolio
    • 11.10.4 Financial Insight